Instrument Inactif

Communiqués RedHill Biopharma Ltd TEL AVIV STOCK EXCHANGE

Actions

IL0011223810

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

RedHill Biopharma Terminates License Agreement for Aemcolo	10/07	AQ
RedHill Biopharma : Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - Form 6-K	03/06	PU
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K	06/05	PU
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035	06/05	PR
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K	24/04	PU
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights	09/04	AQ
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price	03/04	AQ
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K	05/03	PU
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs	05/03	PR
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication	21/02	AQ
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication	20/02	PR
Nasdaq Stocks Under $1 to Watch Now! VTAK, IVP, ONCO, AKTS, RDHL	31/01	AQ
RedHill Biopharma Announces $8 Million Registered Direct Offering	26/01	AQ
RedHill Announces New USPTO Patent Grant for Talicia for H. pylori Treatment Through 2042	26/01	AQ
RedHill Biopharma : and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola - Form 6-K	20/12	PU
RedHill Biopharma : Exercise of Existing Warrants Resulting in $4 Million Proceeds to the Company - Form 6-K	06/12	PU
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study	04/12	PR
Small Cap Companies Spearheading Innovation in the Biopharma Healthcare Sector" INBS, RDHL, CDIO, VTAK, DNA	30/11	AQ
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034	27/11	PR
RedHill Biopharma Announces the Transfer of its Listing to the Nasdaq Capital Market	15/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués RedHill Biopharma Ltd TEL AVIV STOCK EXCHANGE

Actions

IL0011223810

Communiqués

Filtres